Promising source material for winter triticale breeding under the conditions of the Middle Urals

Background. The northern border of cereal crop cultivation passes through the territory of Sverdlovsk Province. Cultivars of winter triticale developed in the regions of Russia located to the south are grown there, but they die under unfavorable winter conditions. The breeding of this crop in local climate is at an early stage, so a study of source material for breeding new highyielding cultivars adapted to local conditions seems quite pertinent.Materials and methods. In 2017–2020, the Ural Research Institute of Agriculture in Yekaterinburg conducted a study of 78 winter triticale genotypes from 10 regions of Russia and 7 foreign countries. The seeds were obtained from the VIR genebank and breeding centers of Russia. Sowing was carried out in clean fallow on August 20–25 on 1 m2 plots in 3-4 repetitions, with the reference ‘Bashkirskaya korotkostebelnaya’ sown on every 10th plot. Plants were assessed for winter hardiness, yield, density of productive stems, plant height, ear length, number of spikelets and grains per ear, weight of 1000 grains, and ear productivity in accordance with published guidelines.Results. Cvs. ‘Privada’, ‘Tsekad 90’ and ‘Nemchinovsky 58’ combined high winter hardiness (70–81%) with resistance to damage by snow mold (15–20%), high density of productive stems (324–425 pcs/m2), and high yield (562–616 g/m2). They had high 1000 grain weight (45.4–49.1 g) and ear productivity (2.63–2.68 g). High yield (571–670 g/m2) and density of productive stems (285–436 pcs/m2 ) with reduced winter hardiness (62–72%) and resistance to snow mold (30–35%) was observed in cvs. ‘Sirs 57’, ‘Sotnik’, ‘Germes’, ‘Antey’, ‘Beta’, ‘Don’, and lines 1/1 and 8003 from Sweden

Cell Therapy for Upper Respiratory Tract Fistulas

Fistulas of various etiologies are one of the severe and life-threatening diseases of the upper respiratory tract. The most common cause is bronchial stump failure after pulmonary resection, usually pneumonectomy. The incidence and mortality of this complication is 3 %-4 % and 12.5 %-71.2 %, respectively. Despite the fact that many devices and methods have been described to date, it is usually treated with surgical closure. Standard surgical approaches are associated with significant morbidity and mortality and are not reliably successful. In recent years, cell therapies aimed to stimulate tissue healing rose to prominence and can be considered a potential treatment method. We review current trends in bronchopleural fistula treatment using cell therapy and report cases of the bronchopleural fistula treatment according to the research protocol developed in our clinic. Although clinical experience is quite limited owing to a small number of patients in the most studies, the information on safety and tolerance can help plan future larger trials with innovative methods to further improve clinical results

Conjugates of 8-[2,2’-bipyridinyl]coumarins as potential chemosensors for Al3+, Cu2+, Cd2+, Zn2+ ions: synthesis and photophysical properties

In this work, we report the synthesis of novel coumarin-bipyridine conjugates using a sequence of C–C coupling reaction between 5,7-dimethoxycoumarins and 3-pyridyl-6-aryl-1,2,4-triazines followed by the Boger reaction with norbornandiene to obtain 8-[2,2'-bipyridyl]-5,7-dimethoxycoumarins. Photophysical properties were investigated for the obtained series of 8-[2,2'-bipyridyl]-5,7-dimethoxycoumarins: absorption and emission wavelength maxima are in the region of 212–296 and 401–410 nm, respectively; Stokes shifts are up to 116 nm, and fluorescence quantum yields are up to 15.0%. It was found that titrating the conjugates with Al3+, Zn2+, and Cd2+ ions results in an increase in the intensity of the emission maxima of the complexes, while the opposite effect was observed in the case of titration with Cu2+ ions. These findings suggest that the studied compounds may be considered as promising chemosensing materials. Finally, a positive solvatochromism of 8-[2,2'-bipyridyl]coumarins and their metal complexes was established. The experimental data are supported by mathematical calculations according to the Lippert-Mataga equation and Kosower diagram

THE ANALYSIS OF RISK FACTORS OF PURULENT-SEPTIC COMPLICATIONS DEVELOPMENT AFTER ABDOMINAL DELIVERY

Purpose: estimation of risk factors and degree of their significance in infectious-inflammatory processes development after Cesarean section.Materials and methods: the retrospective medical documentation analysis of 2235 cases of operative delivery.Results: it is established that antibiotic prophylaxis at a Cesarean section during the investigated period was carried out without contemporary risk factors, an individual estimation of qualitative-quantitative structure genital tract microflora and its account antibiotic -sensitivity in 16.2 % of cases led to nonspecific inflammatory complications development in the postnatal period. Contemporary risk factors of inflammatory complications development in abdominal delivery are revealed.Summary: it is necessary to accomplish a working out and introduction of contemporary and scientifically proved algorithm of purulent-septic complications prevention after abdominal delivery in work of obstetric permanent establishment, taking into account modern risk factors

CONTEMPORARY PROBLEMS OF ABDOMANAL DELIVERY

The review examined Cesarean section significance in decrease of perinatal mortality, the problems associated with the increase of abdominal delivery are reflected, purulent-septic complications are accented, risk factors of infection-inflammatory process development in post operational period are analysed, the advantages and disadvantages of contemporary preventive methods of their origin are considered

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic annotation data along with multi-platform molecular profiles of more than 11,000 human tumors across 33 different cancer types. TCGA clinical data contain key features representing the democratized nature of the data collection process. To ensure proper use of this large clinical dataset associated with genomic features, we developed a standardized dataset named the TCGA Pan-Cancer Clinical Data Resource (TCGA-CDR), which includes four major clinical outcome endpoints. In addition to detailing major challenges and statistical limitations encountered during the effort of integrating the acquired clinical data, we present a summary that includes endpoint usage recommendations for each cancer type. These TCGA-CDR findings appear to be consistent with cancer genomics studies independent of the TCGA effort and provide opportunities for investigating cancer biology using clinical correlates at an unprecedented scale. Analysis of clinicopathologic annotations for over 11,000 cancer patients in the TCGA program leads to the generation of TCGA Clinical Data Resource, which provides recommendations of clinical outcome endpoint usage for 33 cancer types

Origin of Irreversibility of Cell Cycle Start in Budding Yeast

In budding yeast, the commitment to entry into a new cell division cycle is made irreversible by positive feedback-driven expression of the G1 cyclins Cln1,2

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

Background:Sunitinib malate (SUTENT) has promising single-agent activity given on Schedule 4/2 (4 weeks on treatment followed by 2 weeks off treatment) in advanced non-small cell lung cancer (NSCLC).Methods:We examined the activity of sunitinib on a continuous daily dosing (CDD) schedule in an open-label, multicentre phase II study in patients with previously treated, advanced NSCLC. Patients ⩾18 years with stage IIIB/IV NSCLC after failure with platinum-based chemotherapy, received sunitinib 37.5 mg per day. The primary end point was objective response rate (ORR). Secondary end points included progression-free survival (PFS), overall survival (OS), 1-year survival rate, and safety.Results:Of 47 patients receiving sunitinib, one patient achieved a confirmed partial response (ORR 2.1% (95% confidence interval (CI) 0.1, 11.3)) and 11 (23.4%) had stable disease (SD) ⩾8 weeks. Five patients had SD>6 months. Median PFS was 11.9 weeks (95% CI 8.6, 14.1) and median OS was 37.1 weeks (95% CI 31.1, 69.7). The 1-year survival probability was 38.4% (95% CI 24.2, 52.5). Treatment was generally well tolerated.Conclusions:The safety profile and time-to-event analyses, albeit relatively low response rate of 2%, suggest single-agent sunitinib on a CDD schedule may be a potential therapeutic agent for patients with advanced, refractory NSCLC

Diagnostics case of tumorous stages of Kaposi's sarcoma in practice of the dermatovenerologist

The article is devoted to Kaposi's sarcoma, a system disease of vascular genesis, applied to tumors of mesenchyme tissue. Article provides frequency, prevalence, clinical manifestations, examples (occasions) of late - diagnosis. We describe a clinical case of this disease.Статья посвящена системному опухолевому заболеванию сосудистого генеза из числа новообразований дермы и подкожно-жировой клетчатки - саркоме Капоши. Рассмотрены вопросы частоты встречаемости заболевания, вариабельности клинической картины, своевременности постановки клинического диагноза. Описан клинический случай поздней диагностики данного заболевания

Оценка влияния курса терапии инъекционной формой хондроитина сульфата на длительность ремиссии и качество жизни у пациентов с остеоартритом

Ensuring a long-lasting effect of the therapy and its safety are important tasks in the treatment of patients with osteoarthritis (OA). Parenteral forms of chondroitin sulfate (CS) used for the background therapy of OA are characterized by proven efficacy and safety and, compared to oral forms, have greater bioavailability, faster onset of symptom-modifying effect and maintenance of more stable remission, which can significantly improve patients' quality of life.Objective: to evaluate the clinical efficacy and safety of two-month therapy with injectable CS and the duration of positive dynamics after the end of treatment in patients with knee OA (KOA).Material and methods. The open prospective observational study involved 35 patients (mainly women) aged 50–75 years with stage II–III KOA. All patients were prescribed intramuscular therapy with a CS solution (Mucosat® solution), with the first three injections of 1 ml, followed by 2 ml every second day (25 injections in total). Standard indices and questionnaires were used to assess the main clinical indicators at baseline and over time (14, 30, 60 days, 5 and 8 months after the start of treatment), as well as the results of ultrasound examination of the knee at baseline and at the end of treatment.Results and discussion. 14 days after the start of therapy, a statistically significant decrease in pain was observed applying the visual analogue scale (VAS), and after 2 months, 94% of patients had a significant decrease in knee pain according to VAS, Lequesne index and WOMAC index (total score and components). The KOOS parameters and quality of life according to EQ-5D-3L improved significantly. There was no pain or only minor pain (VAS ≤40 mm) in 54% of patients. The number of patients who had to take nonsteroidal anti-inflammatory drugs (NSAIDs) constantly fell threefold, while occasional use fell fivefold. The thickness of the synovial membrane of the knee joint and the number of patients with signs of synovitis decreased significantly. At 3 and 6 months after the end of therapy, most patients (60%) still had minor pain (≤40 mm according to VAS) and a significantly lower need for NSAIDs compared to baseline. The injectable CS was well tolerated and no adverse drug events were noted.Conclusion. We demonstrated both safety and efficacy and long-term maintenance of the clinical effect (6 months after the end of therapy) of injectable CS in the majority of OA patients, against the background of a low need for NSAIDs.Обеспечение пролонгированного эффекта терапии и ее безопасности – важные задачи ведения пациентов с остеоартритом (ОА). Парентеральные формы хондроитина сульфата (ХС), использующегося для базисной терапии ОА, характеризуются доказанной эффективностью и безопасностью и по сравнению с пероральными формами обладают большей биодоступностью, более быстрым наступлением симптом-модифицирующего эффекта и сохранением более стойкой ремиссии, что может значительно улучшать качество жизни пациентов.Цель исследования – оценить клиническую эффективность и безопасность двухмесячного курса терапии инъекционным ХС, а также продолжительность сохранения положительной динамики после окончания лечения у пациентов с ОА коленных суставов (КС).Материал и методы. В открытое проспективное наблюдательное исследование включено 35 больных (преимущественно женщины) 50–75 лет с ОА КС II–III стадии. Всем пациентам был назначен курс терапии раствором ХС (Мукосат® раствор) внутримышечно, первые 3 инъекции по 1 мл, далее по 2 мл через день (всего 25 инъекций). С помощью стандартных индексов и опросников оценивались основные клинические показатели исходно и в динамике (через 14, 30, 60 дней, 5 и 8 мес после начала лечения), а также результаты УЗИ КС исходно и при завершении терапии.Результаты и обсуждение. Статистически значимое уменьшение боли по визуальной аналоговой шкале (ВАШ) отмечено через 14 дней после начала терапии, а через 2 мес у 94% пациентов значимо уменьшились боль в КС по ВАШ, индекс Лекена, индекс WOMAC (общий счет и компоненты). Отмечено значимое улучшение параметров KOOS и качества жизни по EQ-5D-3L. Отсутствие или слабая выраженность боли (ВАШ ≤40 мм) зарегистрированы в 54% случаев. Количество пациентов, нуждавшихся в постоянном приеме нестероидных противовоспалительных препаратов (НПВП), сократилось в 3 раза, в эпизодическом их приеме – в 5 раз. Статистически значимо уменьшились толщина синовиальной оболочки КС, а также число пациентов с признаками синовита. Через 3 и 6 мес после окончания терапии у большинства пациентов (60%) сохранялись незначительная выраженность боли (≤40 мм по ВАШ) и существенно меньшая по сравнению с исходной потребность в НПВП. Переносимость инъекционного препарата ХС была хорошей, нежелательных лекарственных реакций не выявлено.Заключение. Показаны не только безопасность и эффективность инъекционного ХС при ОА, но и длительное сохранение клинического эффекта (6 мес после окончания терапии) у большинства пациентов на фоне низкой потребности в НПВП